News and Events
Replimune Announces First Patients Dosed In A Phase 1/2 Clinical Trial Of Its RP1 Oncolytic Immunotherapy In Patients With Advanced Solid Tumors
– Woburn, MA, November 14, 2017
‘on’ switch for
Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.
Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.
Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.